A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07066657
Phase
PHASE1
Sponsor
ArriVent BioPharma, Inc.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • MRG007
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Denver, Colorado, United States|39.73915,-104.9847
  • Sarasota, Florida, United States|27.33643,-82.53065

Key Eligibility Criteria

  • Willing to sign the informed consent form and follow the requirements specified in the protocol.
  • Life expectancy ≥ 3 months.
  • Tumor specimen available for CDH17 testing, or agree to biopsy at baseline.
  • Patients with histologically and cytologically confirmed advanced or metastatic solid tumor who have failed or intolerant to standard therapy, or w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →